Compare Nucor Corporation (NUE) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nucor Corporation vs Viatris Inc — how do they compare? Nucor Corporation trades at $256.31 (market cap $58.17B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Nucor Corporation is far larger — about 3× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| NUE | VTRS | |
|---|---|---|
Market Cap | $58.17B | $19.09B |
Sector | Basic Materials | Health |
52-Week High | $274.74 | $17.86 |
52-Week Low | $131.78 | $9.49 |
Enterprise Value | $62.58B | $31.21B |
Dividend Yield | 0.87% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nucor Corporation (NUE) trades at $256.40, down 1.79% on the day, with a bullish technical signal supported by moving averages and strong institutional interest. The company shows improving fundamentals with recent earnings beats (Q1 and Q2 2026) and projected revenue growth to $36.1B in 2026. Analyst consensus remains positive with a $277.57 price target, though recent trade tensions and cyclical steel industry challenges present headwinds.
NUE offers value with reasonable valuation multiples (P/E 20.46, P/S 1.63) and strong profitability metrics (ROE 13.52%). Key risks include exposure to steel price volatility and macroeconomic sensitivity, but infrastructure demand and tariff protections provide tailwinds. Institutional accumulation and dividend stability support the investment case for long-term investors.
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
